Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458385 | 0.86 | RXRB (0.37) | FFAR4HTR1ADRD2DRD4 | |
| SCHEMBL13972997 | 0.80 | GRM5 (0.39) | ADORA2AADORA1HTR1ADRD2DRD4 | |
| SCHEMBL4458992 | 0.79 | FFAR4 (0.35) | ADORA2AADORA1TNFRSF1AHDAC8FFAR4 | |
| SCHEMBL4462826 | 0.76 | GRM1 (0.51) | — | |
| SCHEMBL13959327 | 0.72 | HTR1A (0.34) | ADORA2AADORA1HTR1ADRD2DRD4 | |
| SCHEMBL4458994 | 0.69 | HTT (0.48) | — | |
| SCHEMBL6769067 | 0.69 | MCL1 (0.35) | DRD2 | |
| SCHEMBL10475874 | 0.68 | GRM1 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL4454113 | 0.67 | PKM (0.39) | ADORA2AADORA1TNFRSF1AHDAC8FFAR4 | |
| SCHEMBL29150106 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | ADORA2A 42/4885ADORA1 67/4885TNFRSF1A 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.